Multiple sclerosis does not directly cause high blood pressure the way kidney disease or hormonal disorders can, but it creates conditions that make hypertension substantially more likely. Across a study of 37 million electronic health records in the United States, hypertension was about 25% more common in people with MS than in those without it. The connection runs through damaged nerve pathways that regulate blood pressure, medications used to treat MS, reduced physical activity, and overlapping conditions like sleep apnea. None of these pathways operate in isolation, and for many people with MS, several contribute at once.
How Common Is Hypertension in People With MS
The clearest population-level picture comes from that large U.S. analysis of electronic health records. After adjusting for age and sex, the prevalence of hypertension was significantly higher among people with MS across every subgroup examined, including different ages, sexes, and racial backgrounds.1PubMed. The prevalence of hypertension in multiple sclerosis based on 37 million electronic health records from the United States That gap is not a product of MS being diagnosed later in life, when blood pressure naturally creeps up. Even in pediatric-onset MS, the pattern holds: a case-control study found hypertension in roughly 22% of young people with MS compared to about 6% of matched controls.2PubMed. Prevalence of hypertension in pediatric-onset multiple sclerosis and associations with disease course
Seeing the association in children is telling because it narrows the list of possible explanations. Young people with MS have not yet accumulated decades of sedentary habits or long-term medication exposure. Something about the disease itself, or about how it is managed from the earliest stages, seems to tilt the cardiovascular system toward higher pressures.
How MS Disrupts Blood Pressure Regulation
Your body keeps blood pressure stable through a network of sensors and nerve signals, many of which pass through the brainstem. The medulla, a small region at the base of the brain, houses critical circuitry for heart rate, vascular tone, and breathing. When MS plaques land in or near the medulla, they can disrupt these circuits directly. A review of acute cardiac and pulmonary events during MS relapses found that the majority were linked to new demyelinating lesions in the medulla, likely causing excessive activation of the sympathetic nervous system.3PubMed. The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations Overall plaque burden and clinical severity also contribute to cardiovascular dysfunction, not just individual lesion location.4The Neurologist. Cardiovascular Dysfunction in Multiple Sclerosis
Beyond acute episodes, the chronic damage MS causes to autonomic nerve pathways creates a subtler but persistent problem with blood pressure regulation. Your body normally uses a feedback loop called the baroreflex to detect changes in blood pressure and correct them in real time. When blood pressure dips, the baroreflex tightens blood vessels and speeds up the heart; when it rises, the reflex does the opposite. In people with MS, this reflex is blunted. A study comparing people with relapsing-remitting MS to matched healthy controls found that the blood pressure response to a simulated drop in pressure was significantly weaker in the MS group, driven by a reduced ability to tighten blood vessels.5PubMed Central. Impaired carotid baroreflex control of arterial blood pressure in multiple sclerosis
Separate work measuring spontaneous blood pressure and heart rate fluctuations confirmed this picture. Baroreflex sensitivity was roughly half as strong in the MS group as in controls, and the MS group showed greater beat-to-beat variability in systolic blood pressure.6PubMed. Characterisation of cardiac autonomic function in multiple sclerosis based on spontaneous changes of heart rate and blood pressure Another study using direct stimulation of the neck baroreceptors found that the sympathetic arm of the reflex, not just the vagal (heart-rate) side, was impaired in MS patients.7PubMed. Abnormal heart rate and blood pressure responses to baroreflex stimulation in multiple sclerosis patients
What does a sluggish baroreflex mean for blood pressure day to day? It means the system that should be smoothing out pressure swings is not doing its job well. Wide fluctuations in blood pressure are themselves a cardiovascular risk factor, and when the reflex cannot bring pressure down efficiently after it spikes, you spend more time at higher pressures. There is also evidence that people with relapsing-remitting MS have elevated baseline levels of catecholamines, the stress hormones that raise blood pressure by tightening blood vessels and increasing heart rate.8Brain, Behavior, and Immunity. Endocrine and cytokine responses to acute psychological stress in multiple sclerosis So the engine that drives blood pressure up may be running hotter than normal while the brake that should bring it back down is weaker than normal.
MS Medications That Raise Blood Pressure
When you have an MS relapse, the standard treatment is a short course of high-dose intravenous corticosteroids. These drugs are effective at calming inflammation, but they reliably push blood pressure upward. A pilot study using 24-hour ambulatory blood pressure monitoring during corticosteroid treatment found that daytime pressures were higher, especially in patients who already had a personal or family history of hypertension. Nighttime readings were worse in a different way: the normal overnight dip in blood pressure disappeared, and nighttime diastolic pressure landed in a hypertensive range.9PubMed. The effects of high-dose corticosteroids for multiple sclerosis relapse on blood pressure Losing that nighttime dip is a well-recognized cardiovascular risk factor in hypertension research. For someone who receives corticosteroid infusions several times a year, these repeated blood pressure surges add up.
Among longer-term disease-modifying therapies, the picture varies by drug. A nationwide Danish cohort study compared teriflunomide and dimethyl fumarate, two common oral MS medications. The teriflunomide group developed hypertension at roughly three times the rate, with about 41 new hypertension events per 1,000 person-years compared to about 13 for dimethyl fumarate. After adjusting for other risk factors, people on teriflunomide had nearly triple the risk of developing hypertension.10PubMed. Risk of hypertension in patients with multiple sclerosis treated with teriflunomide compared to dimethyl fumarate Teriflunomide’s prescribing information already notes blood pressure elevation as a known side effect, but the magnitude of the difference surprised researchers. Fingolimod, another oral therapy, appears relatively neutral on blood pressure based on hemodynamic measurements in clinical trials, though it does affect heart rate, especially during the first dose.11PubMed Central. Cardiovascular effects of fingolimod: A review article
The practical takeaway is that blood pressure monitoring should be part of routine MS care, not just a box checked at annual physicals. If you are starting or switching disease-modifying therapy, asking about the blood pressure profile of each drug is reasonable, especially if your blood pressure is already borderline.
Sedentary Behavior Hits Harder With MS
People with MS tend to sit more and move less, often because fatigue, spasticity, or mobility problems make activity difficult. That is not surprising. What is more interesting is that the relationship between sitting time and blood pressure appears to be stronger in people with MS than in healthy adults. A study measuring daily sitting time alongside blood pressure found significant positive correlations between time spent sitting and both systolic and diastolic blood pressure in the MS group, but no such correlation in controls. The link held even after accounting for body mass index.12PubMed Central. Sedentary Behavior and Blood Pressure in Patients with Multiple Sclerosis
This suggests that people with MS may be more vulnerable to the cardiovascular effects of inactivity than the general population. A possible explanation involves the autonomic dysfunction discussed earlier. If your baroreflex is already impaired and your baseline sympathetic tone is already elevated, the additional vascular stiffening and deconditioning that come with prolonged sitting may push blood pressure up more readily. Whatever the mechanism, the implication is that even modest increases in daily movement could yield outsized blood pressure benefits for people with MS.
Sleep Apnea and Bladder-Related Complications
Obstructive sleep apnea (OSA) is a well-known driver of hypertension in the general population. Each time breathing stops during sleep, oxygen levels drop and the body triggers a surge in blood pressure. Over months and years, these repeated surges can lead to sustained daytime hypertension. OSA appears to be disproportionately common in people with MS, with some estimates placing prevalence at over 50%, far above general population rates. The reasons likely include brainstem involvement, reduced pharyngeal muscle tone, fatigue-related weight gain, and medication side effects that promote sleep-disordered breathing. If you have MS and uncontrolled blood pressure, untreated sleep apnea is worth investigating.
Bladder dysfunction is another indirect route to blood pressure trouble. Most people with MS experience urinary symptoms at some point, ranging from urgency and frequency to incomplete emptying. MS is recognized as a secondary cause of central autonomic dysfunction, and disorders of urination are among the most common autonomic symptoms the disease produces.13Journal of Neurology. Autonomic dysfunction in multiple sclerosis When the bladder cannot empty properly over years, the backup can reach the kidneys. Persistent urinary retention, recurrent infections, and a condition called detrusor-sphincter dyssynergia all increase the risk of kidney complications including hydronephrosis.14PubMed Central. Renal disease associated with multiple sclerosis: A narrative review Kidney damage from any cause can raise blood pressure by impairing the body’s ability to regulate fluid and sodium. The path from bladder problems to hypertension is long and not inevitable, but it is a recognized concern in advanced MS.
Why Blood Pressure Control Matters More With MS
Hypertension is harmful for everyone, but the consequences appear to be amplified when MS is also present. A study tracking disability progression in MS patients found that those who developed hypertension at any point during follow-up were significantly more likely to reach key disability milestones. Roughly 62% of hypertensive MS patients progressed to an EDSS score of 4 (limited walking ability) compared to about 43% of those without hypertension, and about 51% reached EDSS 6 (needing a walking aid) compared to 28%.15Journal of Clinical Neurology. Disability Progression in Multiple Sclerosis Is Affected by the Emergence of Comorbid Arterial Hypertension Those are large differences that held up across different disability thresholds.
The cardiovascular risks stack up as well. People with MS already face an elevated baseline risk of heart failure, stroke, and heart attack because of factors like inflammation, immune dysfunction, altered clotting, and reduced arterial compliance. When hypertension is added to that picture, the combined risk of severe cardiovascular events climbs further.16The Journal for Nurse Practitioners. Primary Care Management of Hypertension in Patients With Multiple Sclerosis This makes aggressive blood pressure management in MS not just a general-health recommendation but potentially a disease-modifying intervention in its own right. Keeping blood pressure in a healthy range may help slow the accumulation of disability independently of whatever disease-modifying therapy is controlling the immune aspects of MS.
When Brain Scans Create Diagnostic Confusion
There is a practical diagnostic wrinkle worth knowing about. The white matter lesions seen on brain MRI in MS can look similar to the lesions caused by chronic high blood pressure through a condition called cerebral small vessel disease. Both produce bright spots on standard MRI sequences, and in someone with both MS and hypertension, telling which lesions are from which cause becomes genuinely difficult. Researchers have explored advanced imaging techniques, including diffusion tensor imaging and magnetic resonance spectroscopy, to distinguish the two conditions by detecting microstructural differences in brain tissue that looks normal on standard scans.17Egyptian Journal of Radiology and Nuclear Medicine. Differentiating multiple sclerosis from cerebral small vessel disease using diffusion tensor imaging and magnetic resonance spectroscopy on normally appearing thalami
This matters because treatment decisions in MS lean heavily on MRI findings. A neurologist deciding whether to escalate therapy counts new and enlarging lesions. If some of those lesions are actually from poorly controlled blood pressure rather than active MS, the disease may look more aggressive than it truly is, potentially leading to unnecessary treatment changes. Conversely, if hypertensive lesions are mistaken for stable MS burden, the blood pressure problem might not get the attention it deserves. Keeping blood pressure controlled removes one source of diagnostic noise from the MRI picture.
Certain Blood Pressure Drugs in Early Research
An intriguing line of animal research suggests that some classes of blood pressure medication may do more than just lower pressure in the context of MS. A study in mice using a standard model of demyelination found that telmisartan (an angiotensin receptor blocker) and nifedipine (a calcium channel blocker) both improved motor function, restored markers of myelin integrity, and reduced brain inflammation and oxidative stress.18PubMed. Neuroprotective Effects of Telmisartan and Nifedipine Against Cuprizone-Induced Demyelination and Behavioral Dysfunction in Mice The effects appeared to work through anti-inflammatory and antioxidant pathways, not simply through lowering blood pressure.
This is mouse data, not clinical evidence in humans, and the gap between promising animal findings and real-world treatments is vast. Many drugs that protect mouse brains never pan out in human trials. Still, the findings are being watched because people with MS often need blood pressure treatment anyway, and if certain drug classes happen to offer additional brain protection, choosing those preferentially would be a low-risk strategy. Human trials have not yet confirmed whether this translates. For now, the choice of antihypertensive in MS should follow standard guidelines based on effectiveness, side effects, and individual patient factors, with the animal data filed under “encouraging but unproven.”